To partner or not to partner on a new drug launch? Of all the decisions emerging biopharma companies have to make, that's among the most important.

Pharma has come a long way on patient centricity. Regulators, though? Not so much, Treato's CEO says.

Inspired by research at Columbia University—which found Americans spend 95% of their time indoors—Bayer’s new Claritin campaign encourages people to go outside.

The world's best-selling drug, AbbVie's Humira, isn’t worth its current net price—and isn’t as good at its job as two potential competitors. That’s…

Merck & Co. is eyeing Austin, Texas, for a 600-person IT shop, one of four around the globe, as it amps up in personalized and preventative medicine.

Sanofi and Regeneron's cholesterol-fighter Praluent might have had a chance to take the lead in the PCSK9 sales race, but that fuel injection didn’t come…

A few years ago, emerging markets were souped-up engines heating up pharma growth. Now, with economic slowdowns in key markets such as China, they’ve moved…

Roche’s much-anticipated multiple sclerosis drug Ocrevus (ocrelizumab) has topped up with more competitive data that could help it gain a quick hold in the…

Diabetes powerhouse Sanofi and Verily, its tech partner, are plowing close to $500 million into a joint venture that will take their digital disease-management…

Not enough drugmakers on the “smart inhaler” bandwagon for you? Well, go ahead and add AstraZeneca to the list.

Data and Analytics